Program
mavacamten
Also written as “Mavacamten” and “MYK-461”.
Its studies are mostly in Cardiomyopathy, Hypertrophic · Anthrax, led by 2 companies.
Drug pageMYK-461: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 194 open or running | phase 4since Oct 27, 2023 | Dec 19, 2014 | Dec 13, 2027phase 4 · NCT07004972 |
| LianBioits history only | 20 open or running | phase 3since Dec 13, 2021 | Oct 28, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, Dec 19, 2014 to Feb 9, 2018.
- Dec 9, 2016Named mavacamtenINNProposed as its International Nonproprietary Name in WHO's List 116 · before, MYK-461
- Mar 12, 2018Phase 3 study in Cardiomyopathy, HypertrophicNCT03470545 · 251 enrolled · United States, Belgium, Czechia and more
- Apr 5, 2018Phase 2 study in Cardiomyopathy, HypertrophicNCT03496168 · 13 enrolled · United States
- Oct 24, 2018Phase 3 study in Cardiomyopathy, HypertrophicNCT03723655 · 314 enrolled · United States, Belgium, Czechia and more
- Apr 7, 2020Phase 3 study in Cardiomyopathy, HypertrophicNCT04349072 · 112 enrolled · United States
- Feb 16, 2021Phase 2 study in Cardiomyopathy, Familial Restrictive, 3NCT04766892 · 30 enrolled · United States, Canada
- Apr 1, 2022Phase 1 study in AnthraxNCT05320094 · 45 enrolled · United States
- May 2, 2022Phase 1 study in Cardiomyopathy, HypertrophicNCT05362045 · 158 enrolled · United States
- Jun 7, 2022Phase 3 study in Cardiomyopathy, HypertrophicNCT05414175 · 38 enrolled · Japan
- Sep 14, 2022Phase 3 study in Cardiomyopathy, HypertrophicNCT05582395 · 580 enrolled · United States, Australia, Austria and more
- Jan 31, 2023Phase 1 study in Cardiomyopathy, HypertrophicNCT05719805 · 84 enrolled · United States
- Oct 27, 2023Phase 4 study in Cardiomyopathy, HypertrophicNCT06112743 · 63 enrolled · United States, Argentina, Australia and more
- Feb 2, 2024Phase 3 study in Cardiomyopathy, HypertrophicNCT06253221 · 44 enrolled · United States, Australia, Canada and more
- May 26, 2025Phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyNCT07004972 · 50 enrolled · India
- Oct 29, 2026Phase 3 study in CardiomyopathiesNCT07940777 · 500 planned
Ahead
- Dec 13, 2027Primary completion: phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyNCT07004972
- Jul 21, 2029Primary completion: phase 3 study in CardiomyopathiesNCT07940777
TargetBeta
“Cardiac myosin inhibitor”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| omecamtiv mecarbilrule | Cytokinetics | phase 3 | 16 |
| danicamtivrule | Bristol-Myers Squibb | phase 3 | 7 |
Studies
All 19 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07940777Cardiomyopathies | 3 | Not yet recruiting | Jul 21, 2029 | 500 |
| NCT07004972Symptomatic Obstructive Hypertrophic Cardiomyopathy · India | 4 | Active, not recruiting | Dec 13, 2027 | 50 |
| NCT06253221Cardiomyopathy, Hypertrophic · United States, Australia, Canada and more | 3 | Active, not recruiting | Nov 25, 2025 | 44 |
| NCT06112743Cardiomyopathy, Hypertrophic · United States, Argentina, Australia and more | 4 | Active, not recruiting | Jul 16, 2026 | 63 |
| NCT05719805Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Jul 25, 2023 | 84 |
| NCT05582395Cardiomyopathy, Hypertrophic · United States, Australia, Austria and more | 3 | Terminated | Mar 6, 2025 | 580 |
| NCT05414175Cardiomyopathy, Hypertrophic · Japan | 3 | Completed | Nov 27, 2023 | 38 |
| NCT05362045Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Aug 19, 2022 | 158 |
| NCT05320094Anthrax · United States | 1 | Completed | Sep 11, 2022 | 45 |
| NCT04766892Cardiomyopathy, Familial Restrictive, 3 · United States, Canada | 2 | Completed | Feb 26, 2024 | 30 |
| NCT04349072Cardiomyopathy, Hypertrophic · United States | 3 | Completed | Feb 7, 2022 | 112 |
| NCT03723655Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more | 3 | Completed | Jan 16, 2026 | 314 |
| NCT03496168Cardiomyopathy, Hypertrophic · United States | 2 | Completed | Nov 9, 2023 | 13 |
| NCT03470545Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more | 3 | Completed | Mar 14, 2020 | 251 |
| NCT03442764Non-obstructive Hypertrophic Cardiomyopathy · United States | 2 | Completed | Jan 7, 2020 | 59 |
| NCT02842242Cardiomyopathy, Hypertrophic · United States | 2 | Completed | Nov 2017 | 21 |
| NCT02480296Healthy · Australia | 1 | Completed | Jul 2016 | 60 |
| NCT02356289Cardiomyopathy, Hypertrophic · United Kingdom | 1 | Completed | Jul 2015 | 48 |
| NCT02329184Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Mar 2016 | 15 |
How it is read
Names in the registry
- “Mavacamten”, 12 entries
- “mavacamten”, 5 entries
- “MYK-461”, 4 entries
Conditions, from the studies’ own filings
- Cardiomyopathy, Hypertrophic, 18 studies
- Anthrax, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.